Person · CIK 1780235

Niall O'Donnell

No filings in the last two years

Earlier: Mirum Pharmaceuticals, Reneo Pharmaceuticals and Spruce Biosciences

Source: Forms 3, 4, 5 and 144 on SEC EDGAR

Sold on Form 4$6M

Noticed on Form 144$1.4M

Bought on Form 4$14.2M

Companies3

Holdings now

As reported after the latest Form 3, 4 or 5 at each company.

How these figures work

Options and RSUs are from the latest filing that lists them; earlier grants may also be held. Holdings can be out of date when a person stops filing.

Company	Security	Held	Shares or units	As of
Reneo Pharmaceuticals	Common Stock	By RiverVest Venture Fund IV, L.P.	2,188,713	May 8, 2023 · Filing · EDGAR
Reneo Pharmaceuticals	Stock Option (right to buy) exercise $9.01, expires Jun 5, 2033, into Common Stock	Directly	17,500	Jun 6, 2023 · Filing · EDGAR
Spruce Biosciences	Common Stock	By RiverVest Venture Fund IV, L.P.	1,326,305	Feb 16, 2023 · Filing · EDGAR
Spruce Biosciences	Stock Option (Right to Buy) exercise $2.26, expires May 24, 2033, into Common Stock	Directly	30,000	May 25, 2023 · Filing · EDGAR
Mirum Pharmaceuticals	Common Stock	By RiverVest Venture Fund IV, L.P.	1,621,118	Nov 15, 2022 · Filing · EDGAR
Mirum Pharmaceuticals	Stock Option (right to buy) exercise $23.51, expires Jun 1, 2032, into Common Stock	Directly	17,000	Jun 2, 2022 · Filing · EDGAR

Sold and noticed by quarter

Sold (Form 4) Noticed (Form 144) Bought (Form 4)

Quarterly totals as a table

Quarter	Sold (Form 4)	Noticed (Form 144)	Bought (Form 4)
Q3 2023	—	$1.4M	—
Q2 2023	—	—	$1M
Q1 2023	—	—	$2M
Q4 2022	$6M	Not machine-readable	—
Q2 2021	—	—	$3M
Q4 2020	—	—	$3.8M
Q3 2019	—	—	$4.5M

Form 144 notices went onto EDGAR as structured data on April 13, 2023. Earlier notices were filed on paper and cannot be read here, so those quarters show no noticed amount.

Planned sales (Form 144) and the sales that followed

Each Form 144 notice of a planned sale, grouped by broker and 10b5-1 plan, with the Form 4 sales we matched to it.

How we match

A Form 144 is a notice of a planned sale by an affiliate. SEC Tracker matches each notice to Form 4 sales by the same person at the same company within 90 days of the notice, up to the shares noticed. The match is our inference, not something either filing states.

Notice date	Noticed	Planned sale	Outcome	Links
Mirum Pharmaceuticals · Morgan Stanley Smith Barney · No 10b5-1 plan stated · 1 notice
Sep 6, 2023	51,000 · ~$1.4M	Sep 6, 2023	Not sold within 90 days	Filing · EDGAR
Sales without a matching Form 144 · 3 sales No matching Form 144 found. Not every sale needs one: small sales and sales by people who are not affiliates are exempt.
—	—	—	Notice not machine-readable Mirum Pharmaceuticals: Sold 93,770 at $19.69 on Nov 15, 2022 · $1.8M	Filing · EDGAR
—	—	—	Notice not machine-readable Mirum Pharmaceuticals: Sold 32,109 at $19.60 on Nov 14, 2022 · $629K	Filing · EDGAR
—	—	—	Notice not machine-readable Mirum Pharmaceuticals: Sold 174,121 at $19.99 on Nov 11, 2022 · $3.5M	Filing · EDGAR

Every transaction, by company

Each Form 3, 4 and 5 transaction in plain words, newest first.

How these figures work

Values are shares times the price each filing states; grants, exercises and gifts usually state no price. Held after is what the filing reports was held once the transaction was done, directly or through the named holder.

Mirum Pharmaceuticals Director · filings 2019 to 2023 · sold $6M · bought $4.5M · $1.4M noticed on Form 144

Date	Transaction	Shares	Price	Value	Held after	Source
Nov 15, 2022	Open-market or private sale	−93,770	$19.69	$1.8M	1,621,118 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Nov 14, 2022	Open-market or private sale	−32,109	$19.60	$629K	1,714,888 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Nov 11, 2022	Open-market or private sale	−174,121	$19.99	$3.5M	1,746,997 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Jun 2, 2022	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jun 4, 2021	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jun 11, 2020	Grant or award from the company Stock Option (right to buy)	+17,000			17,000 direct	Filing · EDGAR
Jul 22, 2019	Derivative converted	+1,496,118			1,621,118 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Jul 22, 2019	Open-market or private purchase	+300,000	$15.00	$4.5M	1,921,118 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Jul 22, 2019	Derivative converted Series A Preferred Stock	−11,968,944			0 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR

Reneo Pharmaceuticals Director · filings 2021 to 2023 · bought $4M

Date	Transaction	Shares	Price	Value	Held after	Source
Jun 6, 2023	Grant or award from the company Stock Option (right to buy)	+17,500			17,500 direct	Filing · EDGAR
May 8, 2023	Open-market or private purchase	+125,000	$8.00	$1M	2,188,713 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Jun 1, 2022	Grant or award from the company Stock Option (right to buy)	+17,500			17,500 direct	Filing · EDGAR
Apr 13, 2021	Derivative converted	+1,034,600			1,034,600 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Apr 13, 2021	Derivative converted	+829,113			1,863,713 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Apr 13, 2021	Open-market or private purchase	+200,000	$15.00	$3M	2,063,713 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Apr 13, 2021	Derivative converted Series A Preferred Stock	−4,629,630			0 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Apr 13, 2021	Derivative converted Series B Preferred Stock	−3,710,116			0 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Apr 8, 2021	Grant or award from the company Stock Option (right to buy)	+14,000			14,000 direct	Filing · EDGAR

Spruce Biosciences Director · filings 2020 to 2023 · bought $5.7M

Date	Transaction	Shares	Price	Value	Held after	Source
May 25, 2023	Grant or award from the company Stock Option (Right to Buy)	+30,000			30,000 direct	Filing · EDGAR
Feb 16, 2023	Open-market or private purchase	+630,400	$3.17	$2M	1,326,305 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Feb 16, 2023	Open-market or private purchase Common Stock Warrant (Right to Buy)	+472,800			472,800 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
May 25, 2022	Grant or award from the company Stock Option (Right to Buy)	+22,500			22,500 direct	Filing · EDGAR
May 20, 2021	Grant or award from the company Stock Option (Right to Buy)	+10,000			10,000 direct	Filing · EDGAR
Oct 14, 2020	Derivative converted	+445,905			445,905 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Oct 14, 2020	Open-market or private purchase	+250,000	$15.00	$3.8M	695,905 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR
Oct 14, 2020	Derivative converted Series B Preferred Stock	−2,916,664			0 By RiverVest Venture Fund IV, L.P.	Filing · EDGAR

All 19 Forms 3, 4, 5 and 144

Filed	Form	Company	Links
Sep 6, 2023	Form 144	Mirum Pharmaceuticals	Filing · EDGAR
Jun 8, 2023	Form 4	Reneo Pharmaceuticals	Filing · EDGAR
May 26, 2023	Form 4	Spruce Biosciences	Filing · EDGAR
May 16, 2023	Form 4	Spruce Biosciences	Filing · EDGAR
May 10, 2023	Form 4	Reneo Pharmaceuticals	Filing · EDGAR
Nov 15, 2022	Form 4	Mirum Pharmaceuticals	Filing · EDGAR
Jun 6, 2022	Form 4	Mirum Pharmaceuticals	Filing · EDGAR
Jun 3, 2022	Form 4	Reneo Pharmaceuticals	Filing · EDGAR
May 27, 2022	Form 4	Spruce Biosciences	Filing · EDGAR
Jun 8, 2021	Form 4	Mirum Pharmaceuticals	Filing · EDGAR
May 21, 2021	Form 4	Spruce Biosciences	Filing · EDGAR
Apr 15, 2021	Form 4	Reneo Pharmaceuticals	Filing · EDGAR
Apr 12, 2021	Form 4	Reneo Pharmaceuticals	Filing · EDGAR
Apr 8, 2021	Form 3	Reneo Pharmaceuticals	Filing · EDGAR
Oct 16, 2020	Form 4	Spruce Biosciences	Filing · EDGAR
Oct 8, 2020	Form 3	Spruce Biosciences	Filing · EDGAR
Jun 15, 2020	Form 4	Mirum Pharmaceuticals	Filing · EDGAR
Jul 24, 2019	Form 4	Mirum Pharmaceuticals	Filing · EDGAR
Jul 17, 2019	Form 3	Mirum Pharmaceuticals	Filing · EDGAR

Every figure is as filed with the SEC on Forms 3, 4, 5 and 144. Holdings are the amounts reported after each person's latest filing at each company and can be out of date. Matching a Form 144 notice to Form 4 sales is SEC Tracker's inference from owner, company, dates and share counts, not something the filings state. Not investment advice. Not affiliated with the U.S. SEC.

Data on this page was fetched Nov 6, 2026, 7:42 AM ET. The filing on SEC.gov is the record.